Showing 31-40 of 1381 results for "".
Parkinson's Pathology: Elucidating the Role of LRRK2
https://practicalneurology.com/diseases-diagnoses/movement-disorders/parkinsons-pathology-elucidating-the-role-of-lrrk2/30475/Playing a critical role in Parkinson's disease, LRRK2 offers a potential path toward better understanding and potentially treating the condition.Parkinson Disease Therapy: Lifestyle Interventions to Optimize Care
https://practicalneurology.com/diseases-diagnoses/movement-disorders/parkinson-disease-therapy-lifestyle-interventions-to-optimize-care/36278/Lisa Volenec, a patient advocate and General Manager of KMTV, Omaha, NE, shares how incorporating lifestyle modifications—such as diet, exercise, and community engagement—has enhanced her Parkinson disease treatment. She is joined by double-board-certified neurology and lifestyle medicine physician- Therapeutics Q&Ahttps://practicalneurology.com/columns/practice-management/therapeutics-qa/31184/Integrating Antidepressant Therapy in Parkinson’s Disease ManagementDepression is a common comorbidity in Parkinson’s disease (PD) patients, necessitating careful consideration for antidepressant therapy. Dr. Eric J. Ahlskog, a leading neurologist at the Mayo Clinic, emphasizes the interplay between
- Can We Boost The Efficacy of Dopaminergic Therapy?https://practicalneurology.com/columns/practice-management/can-we-boost-the-efficacy-of-dopaminergic-therapy/31220/Parkinson’s disease (PD) management continues to prioritize maintaining patients' quality of life and motor function, aligning with the foundational goals established since Dr. James Parkinson’s initial descriptions in 1817. Contemporary treatment primarily focuses on dopamine replacement to counter
Update on Noninvasive Neuromodulation Devices for Headache Treatment
https://practicalneurology.com/diseases-diagnoses/headache-pain/update-on-noninvasive-neuromodulation-devices-for-headache-treatment/31283/Stewart J. Tepper, MD, Vice President of the New England Institute for Neurology and Headache, Peter McAllister, MD, FAAN, Chief Medical Officer of the New England Institute for Neurology and Headache, and Teshamae Monteith, MD, Associate Professor and Chief of the Headache Division of the DepartmenIn-Focus: Alzheimer's Disease
https://practicalneurology.com/diseases-diagnoses/alzheimer-disease-dementias/in-focus-alzheimers-disease/30347/Generalized Myasthenia Gravis: Inside the MINT Trial and CD19 B-Cell Therapy Advances
https://practicalneurology.com/diseases-diagnoses/neuromuscular/generalized-myasthenia-gravis-inside-the-mint-trial-and-cd19-b-cell-therapy-advances/57164/Richard J. Nowak, MD, MS, Associate Professor of Neurology, Yale School of Medicine, Yale University, New Haven, CT and global principal investigator of the Myasthenia Gravis Inebilizumab Trial (MINT), discusses the phase 3 results, highlighting the safety and efficacy of CD19-targeted B-cell therapLevodopa 2.0: New Strategies to Even Out the Peaks and Valleys
https://practicalneurology.com/diseases-diagnoses/movement-disorders/levodopa-20-new-strategies-to-even-out-the-peaks-and-valleys/30552/An update on the newest pharmacologic options to manage symptoms of PD.- Therapeutics Q&Ahttps://practicalneurology.com/columns/practice-management/therapeutics-qa/31129/Pharmacological Management of Myasthenia Gravis in Young Adults Versus Older PatientsManaging myasthenia gravis (MG) requires tailored pharmacological strategies, especially when comparing young adults to older individuals with similar disease severity. Experts Dr. Henry J. Kaminski and Dr. Zohar Ar
Alpha-Synuclein: A Therapeutic Target and Potential Biomarker in Parkinson's Disease
https://practicalneurology.com/diseases-diagnoses/movement-disorders/alpha-synuclein-a-therapeutic-target-and-potential-biomarker-in-parkinsons-disease/30407/